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using opioids, 44% used short-acting, 19% long-acting, and 37% both. Prevalence of
OpA among those with a history of opioid use was 0.56% compared to 0.06% in
non-users (p0.0001). All HCRU was significantly greater for the pre-index and
post-index periods for OpAers compared to controls (p0.0001). Total health care
costs were greater for OpAers compared with controls; $11,13726,677 versus
$2,2318,438 (p0.0001) in the pre-index and $25,65454,928 vs. $4,90218,682
(p0.0001) in the post-index periods, respectively. Prescription opioid costs for
OpAers and controls was $1,9356844 and $34486 (p0.0001), respectively.
Among OpAers, total healthcare costs were greater for those with pre-index opioid
use compared with those without pre-index opioid use; $13,92030,012 versus
$5,22216,073 (p0.0001) in the pre-index and $29,50056,713 versus
$17,48149,960 (p0.0001) in the post-index periods. CONCLUSIONS: OpAers have
significantly greater HCRU and total cost before and after OpA compared to
matched controls. OpAerswith opioid use had significantly greater total cost before
and after OpA than OpAers without opioid use.
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OBJECTIVES: To identify the incidence and prevalence of idiopathic inflammatory
myopathies (IIMs) among commercially insured and Medicare and Medicaid en-
rolled populations in theUS, using administrative claims data. IIMs are a rare group
of autoimmune syndromes characterized by chronic muscle inflammation and
muscle weakness with no known cause. Little is known about their incidence and
prevalence.METHODS:Medical claims with an IIM diagnosis (ICD-9-CM 710.3 [der-
matomyositis (DM)], 710.4 [polymyositis (PM)], 728.81[interstitial myositis]) were
retrospectively examined in the MarketScan® databases to identify age- and gen-
der-adjusted annual IIM incidence and prevalence for 2004-2008. Sensitivity anal-
ysis was performed for evidence of a specialist visit (rheumatologist/ neurologist/
dermatologist), systemic corticosteroid or immunosuppressant use, or muscle
biopsy. RESULTS: A total of 2990 incident patients between 2004 and 2008 (67%
female, 17% Medicaid enrollees, 27% aged 65 years) were identified. Overall ad-
justed IIM incidence for 2004-2008 for commercial and Medicare supplemental
groups combined were 4.27 cases (95% CI, 4.09-4.44) and for Medicaid, 5.23 (95% CI
4.74-5.72) per 100,000 person-years (py). Disease sub-type incidence rates per
100,000-py were 1.52 (95% CI 1.42-1.63) and 1.70 (1.42-1.97) for DM, 2.46 (2.33-2.59)
and 3.53 (3.13-3.94) for PM, and 0.73 (0.66-0.81) and 0.78 (0.58-0.97) for interstitial
myositis for the commercial/Medicare and Medicaid cohorts respectively. Annual
incidence fluctuated over time with the base MarketScan populations. There were
7,155 prevalent patients, with annual prevalence ranging from 20.62 to 25.32 per
100,000 for commercial/Medicare (83% of prevalent cases) and from 15.35 to 32.74
for Medicaid. Sensitivity analysis reduced the incidence rates and prevalence by
20-40%. CONCLUSIONS: This study found higher IIM incidence and prevalence
than historical small population based reports. Employer turnover, miscoding and
misdiagnosing, care seeking behavior, and fluctuations in database membership
over time can influence the results. Further studies are needed to confirm the
incidence and prevalence of IIMs in the US population.
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OBJECTIVES: Modifiable risk factors in the US workforce have been documented
previously, but knowledge of behavioral risk factor prevalence among working
adults remains incomplete. Toassess currentnational estimates for smoking,heavier
alcohol consumption, obesity, insufficient exercise and fair/poor health status for
working adults aged 20 years and older.METHODS: Analysis of nationally represen-
tative data collected from employed adults 20 years and older participating in the
National Health Interview Survey (NHIS) 2010 (aged 20 to 64 years, n 13,844, aged
20 to 39 years, n6,495, aged 40 to 64 years, n7,349, men aged 20 to 64 years 
6,825, women aged 20 to 64 years  7,019). RESULTS: The prevalence of current
smoking amongworking adults aged 20 to 64 years is 19.6%; younger workers (aged
20 to 39 years) have a significantly higher prevalence of current smoking than
workers 40 to 64 years, (21.2% vs. 18.3%, p0.001) and employed men have a sig-
nificantly higher smoking prevalence than employed women (21.4% vs. 17.6%, re-
spectively, p0.0001). An estimated 5.7% and 5.5% of working men and women,
respectively, report heavier alcohol consumption (p0.5573, 2 drinks/day for men,
1 drink/day forwomen). The prevalence of insufficient exercise is equivalent among
working men and women, 30.6% and 31.0%, respectively. Obesity prevalence in the
workforce is 33.5%; obesity rates are 31.6% and 35.1% among workers 20 to 39 years
and 40 to 64 years, respectively (p0.2665). Employed women and men are equally
likely to report that their health is fair/poor (6.0% vs. 5.1%). CONCLUSIONS: Current
smoking, insufficient exercise and obesity are prevalent in the US workforce. Ef-
fective workplace approaches including increased dissemination of educational
information are needed to reduce the burden of these risk factors.
SYSTEMIC DISORDERS/CONDITIONS – Cost Studies
PSY12
A BUDGET IMPACT ANALYSIS OF TAPENTADOL EXTENDED RELEASE (ER) FOR
THE TREATMENT OF MODERATE TO SEVERE CHRONIC PAIN
Merchant S1, Noe L2, Howe A3, Duff SB4, Gricar J5, Ogden K2, Mody S6
1Janssen Global Services, LLC, Raritan, NJ, USA, 2ICON plc, San Francisco, CA, USA, 3Janssen
Scientific Affairs, LLC, Titusville, NJ, USA, 4Veritas Health Economics Consulting, Carlsbad, CA,
USA, 5Apo-Med, New York, NY, USA, 6Janssen Scientific Affairs, LLC, Raritan, NJ, USA
OBJECTIVES: Tapentadol ER is a new oral analgesic that has been shown to have a
lower incidence of gastrointestinal adverse events (AEs) than oxycodone CR at
equianalgesic doses.We estimated the annual budget impact of placing tapentadol
ER on a health plan formulary of long-acting opioids (LAOs) used to treat moderate
to severe chronic pain. METHODS: An Excel-based budget impact model was de-
veloped to estimate the annual direct healthcare costs associated with long-acting
formulations of tapentadol, oxycodone, morphine, hydromorphone, oxymor-
phone, and fentanyl. Costs included medications, copayments, AE management
and opioid switching/discontinuation. Incidence/prevalence estimates, AEs and
pain management resources and costs (medications, physician phone calls, office
visits, emergency room visits and hospitalizations) were based on published
sources. Drug costswere based onwholesale acquisition cost. All costswere in 2010
US dollars. Weighted-average daily drug consumption (DACON) and formulary
sharewere obtained from IMSHealth. Base case analysis assumed a 10% formulary
share of tapentadol ERwith a 10% decrease of oxycodone CR. Results are presented
as the per-member per-month (PMPM) cost difference after adding tapentadol ER to
the formulary. RESULTS: In a health plan of 500,000 members, 2,600 (0.52%) would
be expected to experience chronic pain annually and be treated with an LAO for an
average of 180 days. Adding tapentadol ER to the formulary (10% share) decreased
both pharmacy (-$0.0136 PMPM) andmedical (-$0.0008 PMPM) costs as well as total
costs (-$0.0144 PMPM), with annual budget savings of $85,992. This was driven by
lower DACON and lower incidence of AEswith tapentadol ER versus oxycodone CR,
leading to reduced resource use and costs. In sensitivity analysis, resultsweremost
sensitive to drug acquisition costs. CONCLUSIONS: Results suggest that increasing
market share of tapentadol ER while reducing oxycodone CR would decrease a
health plan’s budget by decreasing both pharmacy and medical costs.
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OBJECTIVES: Illustrate potential budgetary impact of a risk-share agreement in a
US health plan using a case study of certolizumab pegol (CZP) as treatment for
moderate to severe rheumatoid arthritis (RA).METHODS: An economic model was
developed to evaluate the budget impact to a hypothetical 50 million member
health plan of adding CZP to a formulary. The target population was patients naïve
to TNF inhibitors. Model comparators included adalimumab, etanercept, inflix-
imab, and golimumab. Comparable efficacy is assumed across therapies; discon-
tinuation rates were assumed to differ by therapy, as evidenced by claims data.
Model parameters were estimated using published data, market research, and an
administrative claims database analysis. The base-case included a risk-share com-
ponent for which the health plan received a rebate for clinically non-responsive
CZP patients at week 12. Non-responsive CZP patients were assumed to receive an
alternative TNF-alpha inhibitor for the remainder of the 3-year model horizon.
Analyses captured differences in drug acquisition and intravenous administration
costs for the base-case and an alternate scenario assuming no risk-share agree-
ment. Deterministic sensitivity analyseswere also conducted.RESULTS:Assuming
a risk-share agreement, per-patient per-month (PPPM) savings in years 1, 2, and 3
were $4.22, $2.26, and $2.26, respectively. Applied to a hypothetical health-plan of
50 million members, annual cost savings are $3.6M, $2M, and $2.1M in years 1, 2,
and 3, respectively. Without a risk-share agreement, PPPM savings were $3.27 in
year 1 and $2.21 in years 2 and 3. Model results were most sensitive to average
monthly pharmacy costs of CZP and infliximab. CONCLUSIONS: The analysis sug-
gests that under a risk-share agreement, the addition of CZP to a US health plan
formulary may result in cost savings to the plan. Additionally, even without a
risk-share agreement, the addition of CZP may provide cost savings.
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OBJECTIVES: This study aimed to compare direct healthcare costs and opioid use
over a 1-year period following initiation with duloxetine versus other standard of
care (SOC) treatments among patients with chronic low back pain (CLBP).
METHODS: This retrospective cohort study assessed commercially-insured Mar-
ketscan CLBP patients aged 18-64 years who initiated duloxetine or other treat-
ments (tricyclic antidepressants, venlafaxine, pregabalin, gabapentin, muscle re-
laxants and opioids) in 2009. The first dispense date was defined as the index date.
Selected patientswere required to have at least two lowback pain (LBP) inpatient or
outpatient claims with at least 90 days gap between the 2 in the 12-month pre-
index period. Both duloxetine and SOC cohorts were then matched via propensity
scoring (n668 for each cohort), controlling for demographics, comorbidities, prior
healthcare utilization and costs, and prior medication history. Health care costs
and opioid use (among patients not initiated on opioids) over the 12-month post-
index period were compared between cohorts. RESULTS: Total health care costs
over the 12-month post-index period were $17,435 among duloxetine-initiated pa-
tients, versus $19,633 (p0.1781) for SOC-initiated patients. Duloxetine-initiated
patients also had significantly lower inpatient costs ($3,486 vs. $5,975, p0.0219).
While both groups had similar outpatient costs ($9,558 vs. $10,424, p0.3324),
CLBP-related outpatient costs were significantly lower among duloxetine-initiated
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patients ($1,042 vs. $1,593, p0.0034). The pharmacy costswere, however, higher in
these patients, compared to SOC-initiated patients ($4,358 vs. $3,235, p0.001). In
addition, duloxetine-initiated patients were less likely to use any opioids (56% vs.
63%, p0.05) compared with SOC patients not initiated on opioids. CONCLUSIONS:
Commercially-insured CLBP patients initiating duloxetine were associated with
significantly lower inpatient costs and CLBP-related outpatient costs, but higher
pharmacy costs, compared to patients initiating other SOC treatments. Duloxetine-
initiated patients were also less likely to use opioids in the post-index year.
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OBJECTIVES: The impact of on-demand (OD) treatment for bleeding episodes is
rarely quantified in Italian hemophilia patients with inhibitors. This study calcu-
lated lifetime events, hospitalizations, and quality-of-life (QoL) associated with
recombinant activated Factor VIIa (rFVIIa) and plasma-derived activated pro-
thrombin complex concentrate (pd-aPCC). This study also compared a hypotheti-
cal improved bypassing agent (BA) with faster, more sustained bleed resolution
than rFVIIa against pd-aPCC. METHODS: We developed an Italian semi-Markov
cohort model to reflect treatment effect on bleeds across a lifetime horizon for
2-year old hemophilia patients with high-responding inhibitors. The model tracks
patients through eight health states (pre-ITI, delayed ITI, ITI low dose, ITI high
dose, tolerized, partially-tolerized, non-tolerized, death) in 3-month cycles; bleeds
and treatment success are simulatedwithin states. Published international studies
informed efficacy estimates, and published utility data informed QoL parameter
values. RESULTS: In analysis of rFVIIa vs pd-aPCC, fewer rFVIIa patients required
1 series of home infusions per bleed (13% vs. 40% for pd-aPCC), leading to 4%
fewer hospitalizations following 2 unsuccessful home treatments. QALYs, de-
pendent on tolerization status in the basecase, are 43.13 for rFVIIa vs. 43.06 for
pd-aPCC. Exploratory comparison with improved rFVIIa bleed-resolution showed
reducing the rebleed rate by 15% reduces use of 1 line of therapy by 2%, decreas-
ing hospitalization 13% compared to basecase values. If fewer infusions of the new
BA are required to control a bleed per line of therapy, patients may experience QoL
benefits; utility improvement of 5%-20% raises total QALYs to 43.98-46.54 for the
new BA. CONCLUSIONS: rFVIIa may lower on-demand treatment resource use for
inhibitor patients in Italy, and improving haemostasis of BAs would further im-
prove patient care for this population; additional research around Italian treatment
patterns for inhibitor patients as well as the impact of faster bleed resolution is
warranted.
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OBJECTIVES:To systematically reviewpublished literature assessing the economic
evidence of biologic treatments indicated for Crohn’s disease (CD).METHODS: Pub-
lished articles between January 1995 and June 2011 were searched in PubMed,
EMBASE, ABI/INFORM, Tuft’s Cost-Effectiveness Analysis Registry Database, Co-
chraneNational Health Service Economic Evaluation Database, International Phar-
maceutical Abstracts, Web of Science, and Google Scholar. Studies of interest in-
cluded: 1) cost studies; 2) economic evaluations; or 3) narrative or systematic
reviews related to economic evaluations of biological treatments used for moder-
ate-to-severe CD. Exclusion criteria included the following characteristics: 1) CD-
related cost studies that were narrative or systematic reviews; 2) CD-related cost
studies that did not include costs of biologic treatments; 3) studies published only
as abstracts; or 4) non-English studies. The primary outcomes of interest included
costs associated with biological treatments and cost-effectiveness measures in-
cluding incremental cost-effectiveness ratios. A threshold value of $50,000/QALY
or £30,000/QALY was used to judge treatment cost-effectiveness. RESULTS: Twen-
ty-nine studies were identified, including 12 economic evaluations and 17 cost
studies or reviews of economic evaluations. Economic evaluation studies illus-
trated that infliximab was cost-effective compared with standard care for luminal
CD when provided as induction therapy followed by: 1) episodic therapy over 5 or
more years, or 2) maintenance therapy over one year. Additionally, adalimumab
was found to be more cost-effective than both infliximab and standard care for
luminal CD in terms of 1-year maintenance treatment with or without prior induc-
tion treatment. Cost studies revealed that infliximab usage reduced overall health-
care resource utilization and cost. Older reviews were inconclusive on the cost-
effectiveness of biologic treatments used for CD. CONCLUSIONS: Limited evidence
suggests that biologic treatments are cost-effective for CD under certain clinical
situations. Future studies are recommended to include all indicated biologic treat-
ments to provide a systematic comparison regarding their comparative benefits
and costs.
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OBJECTIVES: This retrospective study aimed to estimate the economic burden
associated with WPL in patients with psoriasis (Pso) in a US based population.
METHODS: Continuously enrolled adult patients with 2 Pso diagnoses were se-
lected from the MarketScan Claims database (2004-2008). Pso patients were
matched (based on age and gender) to continuously enrolled adult Pso-free pa-
tients (i.e., without diagnosis for Pso or psoriatic arthritis). WPL was estimated
using workplace absenteeism and short term disability (STD) expenditures avail-
able in the MarketScan Health and Productivity Management database. Only patients
for whom the employer recorded absenteeism and STD were included in the anal-
ysis. WPL, often referred to as total indirect cost, was defined as the sum of absen-
teeism costs (i.e., hours out of work for medical reasons [sick leave]* hourly wage)
and STD costs (number of days on disability * daily wage). Wages were imputed
based on the regions of residence using data from the U.S. Bureau of Labor Statis-
tics. Annual incremental costs associated with WPL in Pso patients were stratified
by Pso severity (mild or moderate-to-severe) and estimated using generalized lin-
ear models. Moderate-to-severe Pso patients were defined as patients who used
systemic therapies during the 6-month baseline period; mild Pso patients did not
use any systemic therapies during the baseline period. RESULTS: A total of 1137
matched pairs were included. Among Pso patients, 305 (26.8%) had moderate-to-
severe Pso. After adjusting for confounding factors (age and gender), no significant
cost differences associated with WPL were found when comparing mild Pso to
Pso-free patients ($1827 for mild Pso vs. $1770 for Pso-free; difference $52,
p0.825). When compared to Pso-free patients, however, moderate-to-severe Pso
patients were associated with significant incremental WPL of $1026 per patient-
year ($2781 for moderate-to-severe Pso vs. $1770 for Pso-free; p0.014).
CONCLUSIONS: Pso imparts a substantial WPL in patients with moderate-to-se-
vere Pso.
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OBJECTIVES: To estimate incremental resource use and costs of Pso and obesity in
Pso patients.METHODS: Adult Pso patients (2 Pso diagnoses) were selected from
a large US claims database (2004-2008). Pso patients were matched (based on age
and gender) to Pso-free patients (i.e., without Pso or psoriatic arthritis diagnosis).
Obesity was defined based on patients’ reported body mass index (BMI30).
Healthcare resource use and costs were assessed over a one-year period. Incidence
rate differences and incremental annual total health care costs (USD 2010; mea-
sured from a payer perspective) associated with Pso and obesity between Pso and
Pso-free patients were estimated using multivariate Poisson regression models
and generalized linear regressionmodels, respectively, controlling for age, gender,
and Charlson comorbidity index. RESULTS: A total of 1874 matched pairs with
reported BMI were selected. Among Pso patients, 34%were obese compared to 28%
of the Pso-free controls (p0.01). Compared to non-obese Pso patients, obese Pso
patients had on average 7more urgent care visits (hospitalizations and emergency
department visits) per 100 patient-years (p 0.02), and 1.8 more outpatient visits
per patient-years (p0.01). Compared to Pso-free patients, Psowas associatedwith
5.0 more outpatients visits per patient-years in non-obese patients and 6.3 more
outpatients visits per patient-year in obese patients (both p 0.01). Among Pso
patients, obesity presented a $2,729 incremental cost compared to the non-obese
Pso patients ($12,670 vs. $9,192; p0.01). Compared to Pso-free patients, Pso was
associated with a $4,735 incremental total health care cost among non-obese pa-
tients ($9,192 vs. $4,681; p0.01) and a $6,887 incremental cost among obese pa-
tients ($12,670 vs. $5,460; p0.01). The difference ($2152) between $6887 and $4735
was not statistically significant in the final model. CONCLUSIONS: Pso patients
have higher prevalence of obesity when compared to Pso-free patients. Both Pso
and obesity were associated with significant incremental costs.
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OBJECTIVES: Patients with FLT3-mutated AML have poor prognoses due to short
survival, high incidence of relapse, and a lack of effective treatment options. The
objective of this study was to review AML-related literature and estimate the eco-
nomic burden of FLT3-mutated AML in the United States.METHODS: A systematic
literature review was conducted to identify relevant publications from 2000-2011.
Estimates of the epidemiology of FLT3-mutated AML were calculated from SEER
data andUS Census projections. An Excelmodel was developed to estimate the BOI
of FLT3-mutated AML. Resource utilization estimates were obtained from the lit-
erature and expert opinion. RESULTS:A total of 607 citationswere identified and 35
articles abstracted. No direct estimates for the incidence or prevalence of FLT3-
mutated AML in the United States were identified in the literature. The prevalence
of AML in 2008 was obtained from SEER data (27,813 patients aged 20 years). In
2010, it was estimated that 784 adults 60 years and 1,622 adults 60 years were
diagnosed with FLT3-mutated AML. The BOI of FLT3-mutated AML in the US was
estimated at $251 million in 2010, including $191 million in direct costs and $60
million in lost productivity. For newly diagnosed patients60 years, the burden of
FLT3-mutated AMLwas estimated at $90million in 2010. Inpatient hospitalizations
accounted for 36% of direct costs and stem cell transplants for 38%. The cost per
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